Scientific Advisory Board brings together world-class expertise in prostate cancer, hematologic malignancies, molecular imaging, radiochemistry and clinical development

科学顾问委员会汇聚了前列腺癌、血液系统恶性肿瘤、分子成像、放射化学和临床开发领域的世界级专家。

Internationally recognized advisers to support advancement of Actinium's differentiated radioconjugate pipeline across solid tumors and hematologic malignancies

国际公认的顾问团队，以支持Actinium公司在实体瘤和血液系统恶性肿瘤领域中差异化放射性偶联药物管线的推进

NEW YORK

纽约

,

，

Nov. 9, 2026

2026年11月9日

/PRNewswire/ --

/美通社/ --

Actinium Pharmaceuticals, Inc.

锕系制药公司

(NYSE American:

（纽约证券交易所美国市场：

ATNM

ATNM

) ('Actinium' or the 'Company'), a pioneer in the development of targeted radiotherapies, today announced the formation of a Scientific Advisory Board comprising five distinguished clinicians and scientists with extensive experience in oncology, nuclear medicine and radiopharmaceutical development.

）（“Actinium”或“公司”），一家在靶向放射性药物开发领域的先驱企业，今日宣布成立科学顾问委员会，该委员会由五位在肿瘤学、核医学及放射性药物开发领域拥有丰富经验的杰出临床医生和科学家组成。

The Scientific Advisory Board will provide strategic scientific and clinical guidance to support the advancement of Actinium's differentiated radioconjugate pipeline, including ATNM-400, its HER3-targeted alpha radiotherapy currently in a first-in-human Phase 1 study in metastatic castration-resistant prostate cancer.

科学顾问委员会将提供战略性的科学与临床指导，以支持Actinium公司差异化放射性偶联药物管线的推进，包括其靶向HER3的α放射性疗法ATNM-400，该疗法目前正在转移性去势抵抗性前列腺癌患者中开展首次人体I期临床试验。

The Board's collective expertise will support clinical development strategies, trial design, patient selection, molecular imaging and therapeutic combinations across the Company's solid tumor and hematologic malignancy programs..

董事会的集体专业知识将支持公司在实体瘤和血液系统恶性肿瘤项目中的临床开发策略、试验设计、患者选择、分子成像以及联合治疗方案。

'We are pleased to welcome this exceptional group of clinicians and scientists to our Scientific Advisory Board at an important stage in Actinium's development,' said Sandesh Seth, Chairman and Chief Executive Officer of Actinium Pharmaceuticals. 'As we advance ATNM-400 in prostate cancer and pursue broader opportunities across solid tumors and hematologic malignancies, their collective expertise in clinical development, molecular imaging and radiopharmaceutical innovation will be invaluable in helping shape our development strategies.

Actinium Pharmaceuticals 董事长兼首席执行官 Sandesh Seth 表示：“我们很高兴在 Actinium 发展的关键阶段，欢迎这群杰出的临床医生和科学家加入我们的科学顾问委员会。随着我们在前列腺癌领域推进 ATNM-400 的研发，并在实体瘤和血液系统恶性肿瘤领域探索更广泛的机会，他们在临床开发、分子影像以及放射性药物创新方面的集体专业知识，将为塑造我们的开发战略提供宝贵的支持。”

We believe their insights will help us prioritize the most promising opportunities, optimize clinical trial designs and accelerate the development of differentiated targeted radiotherapies for patients with significant unmet medical needs.'.

我们相信，他们的见解将帮助我们优先关注最具前景的机会，优化临床试验设计，并加速开发针对存在重大未满足医疗需求患者的差异化靶向放射疗法。

Actinium's Scientific Advisory Board members include:

Actinium 的科学顾问委员会成员包括：

Karim Fizazi, MD, PhD

卡里姆·菲扎齐，医学博士，哲学博士

- Director General, Centre Oscar Lambret, Lille, France and Professor of Oncology, Paris-Saclay University

- 法国里尔奥斯卡·兰布雷特中心主任，巴黎萨克雷大学肿瘤学教授

Sergio A. Giralt, MD

塞尔吉奥·A·吉拉尔特，医学博士

- Deputy Division Head, Division of Hematologic Malignancies, Melvin Berlin Family Chair in Multiple Myeloma, Memorial Sloan Kettering Cancer Center

- 纪念斯隆-凯特琳癌症中心血液恶性肿瘤科副主任，多发性骨髓瘤梅尔文·柏林家族讲席教授

Jason S. Lewis, PhD

杰森·S·刘易斯，博士

- Emily Tow Chair in Oncology; Deputy Director, Sloan Kettering Institute, Office of Science Education and Training; and Scientific Director, Radiochemistry and Molecular Imaging Probe Core Facility, Memorial Sloan Kettering Cancer Center

- 艾米丽·托肿瘤学讲席教授；斯隆-凯特琳研究所科学教育与培训办公室副主任；纪念斯隆-凯特琳癌症中心放射化学与分子成像探针核心设施科学主任

Michael J. Morris, MD

迈克尔·J·莫里斯，医学博士

- Prostate Cancer Section Head, Memorial Sloan Kettering Cancer Center

- 纪念斯隆-凯特琳癌症中心前列腺癌科室主任

Neeta Pandit-Taskar, MD, MBA

尼塔·潘迪特-塔斯卡尔，医学博士，工商管理硕士

- Professor of Radiology, Chief, Division of Nuclear Medicine, University of Pittsburgh Medical Center

- 匹兹堡大学医学中心放射学教授、核医学科主任

Scientific Advisory Board Member Profiles

科学顾问委员会成员简介

Karim Fizazi, MD, PhD

卡里姆·菲扎齐，医学博士，哲学博士

Dr. Fizazi is an internationally recognized leader in prostate cancer research whose work has helped shape treatment standards for advanced disease. He founded the Prostate Cancer Consortium in Europe (PEACE), creating a collaborative network for large-scale clinical trials, and has authored more than 500 scientific publications.

菲扎齐博士是国际公认的前列腺癌研究领军人物，其研究成果有助于塑造晚期疾病的治疗标准。他创立了欧洲前列腺癌联盟（PEACE），构建了一个用于开展大规模临床试验的合作网络，并已发表500多篇科学论文。

His clinical research spans hormonal therapies, PARP inhibitors, radioligand treatments and innovative treatment combinations. A former Head of the Department of Cancer Medicine at Gustave Roussy, he brings exceptional experience in international drug development, pivotal clinical trials and treatment sequencing for advanced and treatment-resistant prostate cancer..

他的临床研究涵盖激素疗法、PARP抑制剂、放射性配体治疗以及创新联合治疗方案。作为古斯塔夫·鲁西研究所癌症医学系的前主任，他在国际药物研发、关键性临床试验以及晚期和难治性前列腺癌的治疗顺序安排方面拥有卓越的经验。

Sergio A. Giralt, MD

塞尔吉奥·A·吉拉尔特，医学博士

Dr. Giralt is a pioneering transplant physician whose contributions have helped expand access to potentially curative stem cell transplantation. He and his colleagues advanced reduced-intensity conditioning regimens that enabled older and medically vulnerable patients with blood cancers to receive donor transplants, helping change clinical practice worldwide.

吉拉尔特博士是一位开创性的移植医师，他的贡献有助于扩大潜在治愈性干细胞移植的可及性。他和他的同事们推进了降低强度预处理方案，使患有血液癌症的老年及医学上脆弱的患者能够接受供者移植，从而帮助改变了全球范围内的临床实践。

He previously led MSK's Adult Bone Marrow Transplant Service and chaired both the executive board of the Center for International Blood and Marrow Transplant Research and the steering committee of the Blood and Marrow Transplant Clinical Trials Network. His distinguished expertise spans leukemia, multiple myeloma, cellular therapy and innovative conditioning strategies..

他此前曾领导纪念斯隆-凯特琳癌症中心（MSK）的成人骨髓移植服务，并担任国际血液与骨髓移植研究中心执行董事会主席以及血液与骨髓移植临床试验网络指导委员会主席。他的卓越专业专长涵盖白血病、多发性骨髓瘤、细胞疗法以及创新的预处理策略。

Jason S. Lewis, PhD

杰森·S·刘易斯，博士

Dr. Lewis is an internationally recognized radiochemist and innovator at the forefront of molecular imaging and targeted radiopharmaceutical development. He was elected a Fellow of the National Academy of Inventors in 2025 in recognition of inventions supporting novel radiopharmaceuticals and antibody-based diagnostics.

刘易斯博士是国际公认的放射化学家和创新者，处于分子成像和靶向放射性药物开发的前沿。他于2025年当选为美国国家发明家科学院院士，以表彰其在支持新型放射性药物和基于抗体的诊断技术方面的发明贡献。

His laboratory develops cancer-targeting imaging and therapeutic agents, connecting radiochemistry innovation with clinical translation. With expertise spanning radiolabeled antibodies, peptides and small molecules, he brings a distinguished record of scientific innovation directly relevant to the design and development of differentiated radioconjugates..

他的实验室致力于开发靶向癌症的成像和治疗制剂，将放射化学创新与临床转化紧密结合。凭借在放射性标记抗体、肽类和小分子领域的专业知识，他在差异化放射性偶联物的设计与开发方面拥有卓越的科学研究成果。

Michael J. Morris, MD

迈克尔·J·莫里斯，医学博士

Dr. Morris is a leading prostate cancer investigator whose work has helped advance targeted radiopharmaceuticals into clinical practice. He helped lead the pivotal Phase 3 VISION trial of lutetium-177–PSMA-617 and presented its results in the plenary session of the 2021 American Society of Clinical Oncology Annual Meeting.

莫里斯博士是前列腺癌研究领域的领军专家，其工作推动了靶向放射性药物在临床实践中的应用。他协助领导了镥-177–PSMA-617的关键性III期VISION试验，并在2021年美国临床肿瘤学会（ASCO）年会的全体会议上公布了该试验的结果。

VISION supported the initial FDA approval of Novartis Pharma sponsored Pluvicto.

VISION研究支持了由诺华制药赞助的Pluvicto获得美国食品药品监督管理局（FDA）的初始批准。

®

®

, establishing a major advance for patients with metastatic castration-resistant prostate cancer. He is also the lead author of the Phase 3 PSMAfore publication. His experience combines pivotal trial development, molecular imaging and the integration of radiopharmaceuticals with other anti-cancer treatments..

，为转移性去势抵抗性前列腺癌患者取得了重大进展。他也是III期PSMAfore研究论文的主要作者。他的经验涵盖关键临床试验开发、分子成像以及放射性药物与其他抗癌治疗的整合。

Neeta Pandit-Taskar, MD, MBA

尼塔·潘迪特-塔斯卡尔，医学博士，工商管理硕士

Dr. Pandit-Taskar is a distinguished nuclear medicine physician and theranostics leader whose work bridges molecular imaging, individualized radiation delivery and clinical development. She received the Society of Nuclear Medicine and Molecular Imaging's 2023 Henry N. Wagner Jr., MD, Best Paper Award for research on individualized Iomab-B dosing in the Actinium Pharmaceutical sponsored pivotal Phase 3 SIERRA trial, recognizing the meeting's top abstract.

潘迪特-塔斯卡尔博士是一位杰出的核医学医师和诊疗一体化领域的领军人物，其工作横跨分子影像、个体化放射给药和临床开发。她因在锕系制药公司赞助的关键性III期SIERRA试验中开展个体化Iomab-B剂量研究而荣获核医学与分子影像学会颁发的2023年度“小亨利·N·瓦格纳医学博士最佳论文奖”，该奖项旨在表彰会议上的顶级摘要。

She also served as President of SNMMI's Therapy Advisory Committee Center of Excellence from 2021 to 2023. In addition to her departmental leadership, she serves as a vice-chair of clinical translation research and is a medical director of University of Pittsburgh's PET Research Center and oncologic imaging at UPMC Hillman Cancer Center, bringing expertise in imaging, dosimetry and radiopharmaceutical translation..

她还于2021年至2023年期间担任核医学与分子影像学会（SNMMI）治疗咨询委员会卓越中心主席。除了担任系内领导职务外，她还担任临床转化研究副主席，并兼任匹兹堡大学PET研究中心以及UPMC希尔曼癌症中心的肿瘤影像学医疗主任，带来了在影像、剂量学和放射性药物转化方面的专业知识。

About Actinium Pharmaceuticals, Inc.

关于锕系药物公司

Actinium is a pioneer in targeted radiotherapies designed to improve outcomes for patients with cancer. The company employs a biology-driven approach to develop differentiated radiopharmaceuticals for solid tumors and hematologic malignancies. Its mission is to transform cancer treatment through innovative radioconjugates that maximize therapeutic efficacy while minimizing toxicity to healthy tissue by combining expertise in tumor biology, translational medicine, and radiochemistry.

Actinium 是靶向放射疗法领域的先驱，致力于改善癌症患者的治疗结局。公司采用以生物学为驱动的方法，开发用于实体瘤和血液系统恶性肿瘤的差异化放射性药物。其使命是通过创新的放射性偶联药物变革癌症治疗，结合肿瘤生物学、转化医学和放射化学方面的专业知识，在最大化疗效的同时最小化对健康组织的毒性。

Since inception, Actinium has focused on developing innovative radiotherapies. Its pipeline reflects this strategy across three areas: (1) solid tumor therapeutics including ATNM-400 and Actimab-A with pan-tumor potential; (2) Actimab-A as a therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in collaboration with the National Cancer Institute (NCI); and (3) targeted conditioning agents including Iomab-B for bone marrow transplant and Iomab-ACT for cell and gene therapy conditioning.

自成立以来，Actinium 一直专注于开发创新放射性疗法。其产品管线在三个领域体现了这一战略：（1）实体瘤治疗药物，包括具有泛肿瘤潜力的 ATNM-400 和 Actimab-A；（2）与美国国家癌症研究所（NCI）合作，将 Actimab-A 作为急性髓系白血病（AML）和骨髓增生异常综合征（MDS）的治疗基石；（3）靶向预处理药物，包括用于骨髓移植的 Iomab-B 和用于细胞与基因疗法预处理的 Iomab-ACT。

ATNM-400 targets a novel antigen distinct from PSMA and has demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer, and is being evaluated in a first-in-human Phase 1 study in mCRPC. Actimab-A has shown improved survival in relapsed/refractory AML with CLAG-M and is advancing toward a Phase 2/3 trial, with additional development ongoing through a CRADA with the NCI.

ATNM-400 靶向一种不同于 PSMA 的新型抗原，并在转移性去势抵抗性前列腺癌（mCRPC）、非小细胞肺癌（NSCLC）和乳腺癌中显示出临床前活性，目前正在 mCRPC 患者中进行首次人体 I 期临床研究。Actimab-A 在与 CLAG-M 方案联用时，已显示出可改善复发/难治性急性髓系白血病（AML）患者的生存期，正推进至 II/III 期临床试验，并通过与美国国家癌症研究所（NCI）的合作研发协议（CRADA）开展进一步开发。

Actinium is also advancing preclinical solid tumor programs and holds ~250 patents and patent applications, including intellectual property related to cyclotron-based production of Ac-225. For more information, please visit .

Actinium 也在推进临床前实体瘤项目，拥有约 250 项专利和专利申请，包括与基于回旋加速器生产 Ac-225 相关的知识产权。欲了解更多信息，请访问 。

www.actiniumpharma.com

www.actiniumpharma.com

.

。

Forward-Looking Statements

前瞻性陈述

This press release may contain projections or other 'forward-looking statements' within the meaning of the 'safe-harbor' provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update.

本新闻稿可能包含根据1995年《私人证券诉讼改革法案》的“安全港”条款所定义的预测或其他“前瞻性陈述”，涉及未来事件或公司未来的财务表现，公司不承担更新这些陈述的义务。

These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with the conduct, timing and results of the Company's ongoing first-in-human Phase 1 study, including the risk that interim findings are not predictive of final results and that preclinical results are not predictive of results in humans, preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the 'SEC'), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time..

这些陈述基于管理层当前的预期，并受到各种风险和不确定性的影响，可能导致实际结果与预期或估计的未来结果存在重大差异，包括与公司正在进行的首次人体一期临床试验的实施、时间安排和结果相关的风险和不确定性，其中包括中期发现不能预测最终结果的风险以及临床前结果不能预测人体试验结果的风险、初步研究结果与最终结果存在差异的风险、对正在开发药物的潜在市场估计、临床试验、美国食品药品监督管理局（FDA）及其他政府机构的行为、监管批准、对监管事项的回应、市场对Actinium产品和服务的需求及接受程度、临床研究组织的表现，以及Actinium在向美国证券交易委员会（“SEC”）提交的文件中不时详述的其他风险，包括但不限于其最新的10-K表格年度报告、后续的10-Q表格季度报告和8-K表格报告，各文件均经不时修订和补充。

Investors Contact:

投资者联系：

Peter (PJ) Kelleher

彼得（PJ）凯莱赫

LifeSci Advisors

LifeSci 顾问

pkelleher@lifesciadvisors.com

pkelleher@lifesciadvisors.com

(617) 430-7579

(617) 430-7579

SOURCE Actinium Pharmaceuticals, Inc.

来源：Actinium Pharmaceuticals, Inc.